Trial Profile
A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms SALUTE-D
- Sponsors Novartis
- 31 Oct 2017 Status changed from recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.